Oncolytic virus startup TILT raises €22M to advance cancer therapies
Finland-based TILT Biotherapeutics announced today it raised €22 million in the final close of a second round of financing to push its oncolytic virus pipeline into Phase II trials. The company raised €10 million in the first round in June of last year.
A chunk of the second round, €5.9 million, comes from the European Innovation Council Fund with another €2.1 million grant from EIC’s Accelerator program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.